Dr. David Feifel discusses psilocybin’s breakthrough potential for treatment-resistant depression, the psychedelic renaissance, and preparing for a new era in psychiatry.
Editorial Focus
The Evolving Psychedelic Paradigm
Recent JCP Articles on Evolving Psychedelics
Behind the Manuscript: The Psychedelic Renaissance and Treatment-Resistant Depression with David Feifel, MD, PhD
Listen to the Podcast
Recent PCC Articles on Evolving Psychedelics
More Articles on Evolving Psychedelics
Original Research
CBT following Esketamine for Major Depression and Suicidal Ideation for Relapse Prevention: The CBT-ENDURE Randomized Trial
May 4, 2026
In patients with major depression and suicidal ideation, adding a 16-week CBT course to esketamine led to greater improvements in suicidal ideation and depression severity than esketamine alone.
Consensus Statement
Next-Step Treatment Options for Treatment-Resistant Depression
January 21, 2026
Strong consensus emerged for augmentation with second-generation antipsychotics, TMS, and ketamine/esketamine in the base vignette. Preferences shifted to include non-augmentative antidepressants and ECT based on patient characteristics.
Case Series
Esketamine Augmented With Dextromethorphan/Bupropion for Treatment Resistant Depression: A Case Series
November 3, 2025
Three patients with TRD who had no or partial response to esketamine monotherapy as part of a clinical trial received augmentation with dextromethorphan/bupropion 45 mg/105 mg daily.
Original Research
Comparing the Cognitive Effects of Repeated IV Ketamine and ECT in Patients with Treatment-Resistant Depression: A Secondary Analysis of the ELEKT-D Trial
September 3, 2025
Patients treated with ketamine demonstrated superior cognitive functioning compared with those treated with ECT following a 3-week treatment course. No differences between treatments were observed among responders in at…
